Jane A. Little
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jane A. Little has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Mariam Kayle
Duke University School of Nursing, Durham, NC, USA
2 shared publications - Mofiyin A. Obadina
Division of Hematology, Department of Medicine University of North Carolina Chapel Hill North Carolina USA
2 shared publications - Olu Jegede
Cone Health Sickle Cell Program Greensboro, NC, 27403
2 shared publications - Payal Desai
10Atrium Health Levine Cancer Institute, Department of Cancer Medicine, Wake Forest University School of Medicine, Charlotte, NC
2 shared publications - Ada Chang
UNC Blood Research Center, University of North Carolina , Chapel Hill, NC 27514
1 shared publication Alan C. Kinlaw
GSK PLC Durham North Carolina USA
1 shared publication
Latest Publications
- 27 September 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (5) , 2389-2391
RESOLVE to do better
Commentary on: Long Title: Phase 3, randomised, placebo‐controlled trial of Voxelotor for the resolution of leg ulcers in sickle cell disease: RESOLVE. Br J Haematol. 2026;209:2252–2263.
- 27 September 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (5) , 2389-2391
RESOLVE to do better
Commentary on: Long Title: Phase 3, randomised, placebo‐controlled trial of Voxelotor for the resolution of leg ulcers in sickle cell disease: RESOLVE. Br J Haematol. 2026;209:2252–2263.
- Open Access
- 17 April 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (7) , 1665-1669
High‐Altitude Hypoxemia in Adults With Sickle Cell Disease ( SCD )
- 17 April 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (7) , 1665-1669
Open AccessHigh‐Altitude Hypoxemia in Adults With Sickle Cell Disease ( SCD )
- Open Access
- 15 January 2026
- Published by Oxford University Press (OUP) in Journal of Sickle Cell Disease
- Vol. 3 (1)
Trajectories of emergency department use among adolescents and young adults with sickle cell disease in North Carolina
Objectives: Emergency department (ED) utilization among transition age adolescents and young adults (AYAs, 14-30 years old) with SCD is linked to morbidity and mortality. We describe age-related ED utilization and associations with sociodemographic characteristics among AYAs with SCD in North Carolina (NC). Methods: This observational study used the NC Hospital Discharge data (2014-2019). We conducted latent growth class analysis to identify distinct ED utilization trajectories by age and bivariate analyses to explore associations between ED utilization classes and sociodemographic factors. Results: During the study, 3614 AYAs with SCD (54% female; 96% Black) had 39 585 ED visits. The mean number of annual ED visits was 1.23 at age 14, peaking at 5.35 at age 24, and declining to 4.64 at age 30. Three classes of ED utilization trajectories were identified: low [95.2%, mean (SD) annual visits = 2.29 (2.55)], medium [4.1%, mean (SD) annual visits = 20.38 (7.42)], and high [0.7%, mean (SD) annual visits = 47.71 (18.58)]. Despite similar utilization at age 14, medium and high utilization groups had respectively 10 and 20 times the ED utilization of the low utilization group and had visits at multiple EDs. Social vulnerability was not associated with ED utilization. Conclusion: A small fraction of AYAs drive most ED utilization, with significant increases observed during transition. These results underscore the necessity for resources and tailored interventions to enhance care continuity during transition. Further research should identify modifiable factors influencing ED visits and develop strategies to improve transition care.
- 15 January 2026
- Published by Oxford University Press (OUP) in Journal of Sickle Cell Disease
- Vol. 3 (1)
Open AccessTrajectories of emergency department use among adolescents and young adults with sickle cell disease in North Carolina
Objectives: Emergency department (ED) utilization among transition age adolescents and young adults (AYAs, 14-30 years old) with SCD is linked to morbidity and mortality. We describe age-related ED utilization and associations with sociodemographic characteristics among AYAs with SCD in North Carolina (NC). Methods: This observational study used the NC Hospital Discharge data (2014-2019). We conducted latent growth class analysis to identify distinct ED utilization trajectories by age and bivariate analyses to explore associations between ED utilization classes and sociodemographic factors. Results: During the study, 3614 AYAs with SCD (54% female; 96% Black) had 39 585 ED visits. The mean number of annual ED visits was 1.23 at age 14, peaking at 5.35 at age 24, and declining to 4.64 at age 30. Three classes of ED utilization trajectories were identified: low [95.2%, mean (SD) annual visits = 2.29 (2.55)], medium [4.1%, mean (SD) annual visits = 20.38 (7.42)], and high [0.7%, mean (SD) annual visits = 47.71 (18.58)]. Despite similar utilization at age 14, medium and high utilization groups had respectively 10 and 20 times the ED utilization of the low utilization group and had visits at multiple EDs. Social vulnerability was not associated with ED utilization. Conclusion: A small fraction of AYAs drive most ED utilization, with significant increases observed during transition. These results underscore the necessity for resources and tailored interventions to enhance care continuity during transition. Further research should identify modifiable factors influencing ED visits and develop strategies to improve transition care.
- Open Access
- 15 January 2026
- Published by Oxford University Press (OUP) in Journal of Sickle Cell Disease
- Vol. 3 (1)
A public health led, statewide approach to improving emergency department care for individuals with sickle cell disease—North Carolina
Sickle cell disease (SCD) is a lifelong condition affecting approximately 100 000 individuals in the United States. It causes progressive organ damage through hemolysis, vaso-occlusion, and chronic inflammation. Patients frequently present to emergency departments (EDs) for acute complications, most commonly severe pain episodes. Unfortunately, acute care encounters are often characterized by negative interactions between patients and providers, fostering mutual distrust and dissatisfaction. In response to community input, the North Carolina Governor’s Council on Sickle Cell Syndrome Medical Research Committee partnered with medical centers, the North Carolina Department of Health, and community-based organizations to implement standardized guidelines for SCD care statewide. Using state-level data, the initiative targeted the 20 ED sites with the highest visit volumes. Each site received an implementation toolbox, developed by the committee and designed to improve emergency care. Following formal outreach, expert consultants engaged site representatives to review the toolbox and initiate discussions on best practices, including Emergency Severity Index (ESI) triage protocols and individualized care plans. Monthly expert consultation (committee members) follow-up calls were established to monitor progress and sustain engagement. Additional efforts were directed toward sites that did not initially respond to formal outreach. To further support the care of patients with complex health care needs who receive care at multiple institutions, we established a multi-institutional monthly virtual patient care conference focused on pain management in high needs patients and sites were invited to participate. This initiative reports a public health program to improve ED care for persons living with SCD.
- 15 January 2026
- Published by Oxford University Press (OUP) in Journal of Sickle Cell Disease
- Vol. 3 (1)
Open AccessA public health led, statewide approach to improving emergency department care for individuals with sickle cell disease—North Carolina
Sickle cell disease (SCD) is a lifelong condition affecting approximately 100 000 individuals in the United States. It causes progressive organ damage through hemolysis, vaso-occlusion, and chronic inflammation. Patients frequently present to emergency departments (EDs) for acute complications, most commonly severe pain episodes. Unfortunately, acute care encounters are often characterized by negative interactions between patients and providers, fostering mutual distrust and dissatisfaction. In response to community input, the North Carolina Governor’s Council on Sickle Cell Syndrome Medical Research Committee partnered with medical centers, the North Carolina Department of Health, and community-based organizations to implement standardized guidelines for SCD care statewide. Using state-level data, the initiative targeted the 20 ED sites with the highest visit volumes. Each site received an implementation toolbox, developed by the committee and designed to improve emergency care. Following formal outreach, expert consultants engaged site representatives to review the toolbox and initiate discussions on best practices, including Emergency Severity Index (ESI) triage protocols and individualized care plans. Monthly expert consultation (committee members) follow-up calls were established to monitor progress and sustain engagement. Additional efforts were directed toward sites that did not initially respond to formal outreach. To further support the care of patients with complex health care needs who receive care at multiple institutions, we established a multi-institutional monthly virtual patient care conference focused on pain management in high needs patients and sites were invited to participate. This initiative reports a public health program to improve ED care for persons living with SCD.
- 30 December 2025
- Published by Wiley in European Journal of Haematology
- Vol. 116 (4) , 425-434
Low Use of FDA ‐Approved Medications for Sickle Cell Disease in Adults
As the landscape of treatments for sickle cell disease (SCD) shifts, relatively little is known regarding the rates of medication prescription for SCD at a population level. This study was a cross‐sectional annualized cohort analysis that used North Carolina Medicaid claims data from 2018 through 2022 to examine rates of prescription of FDA‐approved medications for SCD and factors associated with their use. Adults with SCD were identified using a standard administrative data algorithm, and their data were aggregated to the person‐year level. Annual prescription rates (≥ 1 claim) of hydroxyurea, L‐glutamine, voxelotor, crizanlizumab, and opioid analgesics were calculated over time, and binomial mixed effects models examined associations between prescription and individual characteristics. Among 1733 individuals, the rate of hydroxyurea prescription ranged from 24.2%–26.7%. Rates for L‐glutamine, voxelotor, and crizanlizumab were less than 6.0% each year. The rate of opioid prescription ranged from 51.4%–53.9%. Seeing a hematologist was consistently associated with higher odds of receiving SCD‐specific medications. Age was associated with decreased prescription of hydroxyurea, L‐glutamine, and opioids, but increased prescription of voxelotor. Males had higher odds of receiving hydroxyurea. Although use of FDA‐approved medications for SCD was low, improved access to hematologists may increase medication utilization.
- 30 December 2025
- Published by Wiley in European Journal of Haematology
- Vol. 116 (4) , 425-434
Low Use of FDA ‐Approved Medications for Sickle Cell Disease in Adults
As the landscape of treatments for sickle cell disease (SCD) shifts, relatively little is known regarding the rates of medication prescription for SCD at a population level. This study was a cross‐sectional annualized cohort analysis that used North Carolina Medicaid claims data from 2018 through 2022 to examine rates of prescription of FDA‐approved medications for SCD and factors associated with their use. Adults with SCD were identified using a standard administrative data algorithm, and their data were aggregated to the person‐year level. Annual prescription rates (≥ 1 claim) of hydroxyurea, L‐glutamine, voxelotor, crizanlizumab, and opioid analgesics were calculated over time, and binomial mixed effects models examined associations between prescription and individual characteristics. Among 1733 individuals, the rate of hydroxyurea prescription ranged from 24.2%–26.7%. Rates for L‐glutamine, voxelotor, and crizanlizumab were less than 6.0% each year. The rate of opioid prescription ranged from 51.4%–53.9%. Seeing a hematologist was consistently associated with higher odds of receiving SCD‐specific medications. Age was associated with decreased prescription of hydroxyurea, L‐glutamine, and opioids, but increased prescription of voxelotor. Males had higher odds of receiving hydroxyurea. Although use of FDA‐approved medications for SCD was low, improved access to hematologists may increase medication utilization.
- Open Access
- 17 January 2025
- Published by Oxford University Press (OUP) in Journal of Sickle Cell Disease
- Vol. 2 (1) , yoaf003
Nocturnal hemoglobin desaturation in chronically transfused adults with sickle cell disease: a retrospective study
High-risk SCD may be managed with chronic red blood cell exchange transfusions. We examined the prevalence of sleep-associated hypoxemia (≥5 minutes at SpO2 ≤88%) or nocturnal Hb desaturation (NHD) in chronically transfused adults with SCD. Of 41 identified participants, 15 (36.6%) had tested positive for NHD at some point prior to enrollment. The median duration of desaturation (SpO2 ≤88%) in those that tested positive was 88.3 minutes (IQR 27.9-226.0 minutes). Participants with and without NHD were compared using non-parametric statistical tests. Compared to participants without NHD, those with NHD had higher absolute reticulocyte counts (P = .018) and white blood counts (P = .05) and tended to be older. They had more anemia (P = .11) and higher lactate dehydrogenase levels (P = .072). Older age at initiation of chronic red blood cell transfusions associated the strongest with a longer duration of NHD (ρ = 0.4253, P = .0067), while prior history of cerebrovascular events associated with a shorter duration of NHD (P = .0315). Our results demonstrate that NHD is common in adults being treated with red blood cell exchange for high-risk SCD and associates with laboratory evidence of increased disease activity. Increased awareness of this complication and appropriate screening may provide an additional simple, low-cost, and physiologically relevant treatment intervention, that is oxygen therapy.
- 17 January 2025
- Published by Oxford University Press (OUP) in Journal of Sickle Cell Disease
- Vol. 2 (1) , yoaf003
Open AccessNocturnal hemoglobin desaturation in chronically transfused adults with sickle cell disease: a retrospective study
High-risk SCD may be managed with chronic red blood cell exchange transfusions. We examined the prevalence of sleep-associated hypoxemia (≥5 minutes at SpO2 ≤88%) or nocturnal Hb desaturation (NHD) in chronically transfused adults with SCD. Of 41 identified participants, 15 (36.6%) had tested positive for NHD at some point prior to enrollment. The median duration of desaturation (SpO2 ≤88%) in those that tested positive was 88.3 minutes (IQR 27.9-226.0 minutes). Participants with and without NHD were compared using non-parametric statistical tests. Compared to participants without NHD, those with NHD had higher absolute reticulocyte counts (P = .018) and white blood counts (P = .05) and tended to be older. They had more anemia (P = .11) and higher lactate dehydrogenase levels (P = .072). Older age at initiation of chronic red blood cell transfusions associated the strongest with a longer duration of NHD (ρ = 0.4253, P = .0067), while prior history of cerebrovascular events associated with a shorter duration of NHD (P = .0315). Our results demonstrate that NHD is common in adults being treated with red blood cell exchange for high-risk SCD and associates with laboratory evidence of increased disease activity. Increased awareness of this complication and appropriate screening may provide an additional simple, low-cost, and physiologically relevant treatment intervention, that is oxygen therapy.
- Open Access
- 30 November 2023
- Published by American Society of Hematology in Blood
- Vol. 142 (22) , 1854-1856
Cold comfort in sickle cell disease
In this issue of Blood, Ivy et al1 show that the alternative complement pathway drives vaso-occlusion and pain after cold exposure in a mouse model of sickle ce
- 30 November 2023
- Published by American Society of Hematology in Blood
- Vol. 142 (22) , 1854-1856
Open AccessCold comfort in sickle cell disease
In this issue of Blood, Ivy et al1 show that the alternative complement pathway drives vaso-occlusion and pain after cold exposure in a mouse model of sickle ce
- Open Access
- 10 November 2022
- Published by American Society of Hematology in Blood
- Vol. 140 (19) , 2005-2006
RBC, heal thyself: PK activators in SCD
In this issue of Blood, Xu et al1 open the hood of the sickle hemoglobin (HbS)–containing red blood cells (RBCs) and cleverly soup up the carburetor; that is, t
- 10 November 2022
- Published by American Society of Hematology in Blood
- Vol. 140 (19) , 2005-2006
Open AccessRBC, heal thyself: PK activators in SCD
In this issue of Blood, Xu et al1 open the hood of the sickle hemoglobin (HbS)–containing red blood cells (RBCs) and cleverly soup up the carburetor; that is, t